Effects of Traditional Chinese Medicine on Outcomes in Patients With AECOPD Risk Window
Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Chronic Obstructive Pulmonary Disease focused on measuring Chronic Obstructive Pulmonary Disease, Acute Exacerbation Risk Window, Traditional Chinese Medicine, Randomized Controlled Trial
Eligibility Criteria
Inclusion Criteria:
- A confirmed diagnosis of AECOPD Risk Window;
- Age ranges from 40 years to 80 years;
- Syndrome differentiation meets criteria of qi deficiency and internal cold fluid syndrome, qi and yin deficiency and unclean phlegm heat syndrome, or lung and spleen qi deficiency and phlegm-damp amassing in lung syndrome;
- Without participations in other interventional trials in the previous one month;
- With the informed consent signed.
Exclusion Criteria:
- Pregnant and lactating women;
- Dementia, mental disorders and reluctant partners;
- Complicated with heart failure (NYHA Class IV), or Serious cardiac arrhythmias, or unstable hemodynamics;
- Current respiratory disorders other than COPD (e.g., bronchiectasis, active tuberculosis, pneumothorax, Pleural effusion, pulmonary thromboembolic, or Neuromuscular diseases affect respiratory movement function);
- Complicated with serious hepatic and renal diseases (liver cirrhosis, portal hypertension, bleeding of varicose veins, dialysis, or renal transplantation);
- Bedridden for various reasons;
- Allergic to the used medicine.
Sites / Locations
- The First Affiliated Hospital of Henan University of Traditional Chinese MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
TCM granule plus conventional drug
TCM placebo granule plus conventional drug
The experimental group will receive three types of TCM granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.
The control group will receive three types of TCM placebo granule and conventional drug according to 2020 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Medicine Diagnosis Treatment Guidelines.